There are 67 proteins in the human mitochondrial transport protein family. They have been identified from among the proteins of the RefSeq database on the basis of sequence similarity to proteins that have been functionally identified as mitochondrial transport proteins. They have also been identified by matching their predicted structure to the high resolution structure of the bovine ADP/ATP T1 transporter subunit/ carboxyatractyloside complex. 74 nonsynonymous single nucleotide polymorphisms (nsSNP) have been identified in their gene sequences. These nsSNPs are present in genes of 30 of the proteins. No nsSNP has been found in 24 of the protein genes and no search has as yet been carried out on the rest (13) of them. The largest number of nsSNPs are in the ADP/ATP T3 transporter, the uncoupling protein 3 L, and the phosphate transporter genes with 7, 6, and 6, respectively. nsSNPs are located in groups along the protein sequence suggesting that certain protein domains are too critical for transport function to tolerate mutations. This interpretation has been validated with mutation and function studies of the phosphate transporter. Human diseases have been identified with replacement mutations in seven of these proteins. Their genes are not abnormally susceptible to mutations since they have the smallest number of nsSNPs. Disease causing mutations have also been observed as: substitution, silent (may affect stability of messages), frameshift (protein truncation or elongation), splicing (exon skipping), residue deletion. Disease causing mutations have only been identified in few transporter genes because others do not yield dramatic symptoms or are essential and thus lethal. Mutations in other transporter genes may also only have a major impact through their combination with other genes and their nsSNPs.
Introduction
Cytosolic metabolic pathways often carry out several of their essential reactions within the mitochondrial matrix. This requires that charged metabolites must cross the mitochondrial inner membrane. Transfer of charged metabolites across this membrane in an uncontrolled manner will be deleterious to the membrane potential that is essential for oxidative phosphorylation. A cell that becomes deficient in ATP is almost certain to suffer cell death. The mitochondrial transport proteins have the essential role of transporting charged metabolites in a highly controlled manner across the mitochondrial membrane while retaining the membrane potential that is essential for oxidative phosphorylation. At the same time the transporters also have to insure that metabolites are transported across the mitochondrial membrane at a rate sufficient to satisfy the needs of the metabolic pathways.
With the availability of the human genome and extensive analyses that have already been carried out, it has become clear that there are over 65 transport proteins in human mitochondria [1] . Additional proteins that do not belong to this transporter family transport metabolites and other substances across the mitochondrial membrane [2, 3] . This communication concerns itself only with transport proteins that belong to the human mitochondrial (continued on next page) transport protein family [1, 4] . It calls attention to the issue of mutations that can yield partial inhibition of transport activity. Such partial inhibition of a single transporter or in combination with partial inhibitions of other transport protein activities can significantly impact cellular metabolism. This communication identifies replacement mutations due to the nonsynonymous SNPs of the human mitochondrial transport proteins (http://www.ncbi.nlm.nih.gov/SNP/). Also identified have been the mutations in the human transport proteins that have been shown to cause human diseases. These data have been combined with the extensive research results on mutations of the mitochondrial phosphate transport protein [5] to identify patterns of inhibitory and non-inhibitory mutations that may be common to all mitochondrial transport proteins. Table 1 shows the human mitochondrial transport proteins as they have been identified from the RefSeq database (http:// www.ncbi.nlm.nih.gov/genome/guide/human/). This total number of proteins changes somewhat as it becomes clearer which proteins are expressed, which have been incorrectly predicted, and which have been published with minor differences that proved to be incorrect. Some of the proteins are partial sequences of others. Nevertheless their existence is highly probable since their sequences were obtained from cDNA libraries. It is important to characterize the functions of such partial sequences.
Results and discussions
The data in Table 1 also show replacement mutations due to single nucleotide polymorphisms (SNPs) in the transport protein genes. Much effort is currently being placed into the identification of gene pools based on single nucleotide differences between genes of individuals. The expectation is that correlations can be made between certain gene pools and common diseases such as cancer, stroke, heart disease, diabetes, depression, and asthma which in most cases have not been successfully identified with a mutation in a single gene. These efforts should also lead to a tailoring of individual doses of pharmaceuticals to individuals and to a minimizing of side effects due to pharmaceuticals.
In Table 1 are shown only the nonsynonymous SNP (nsSNP) since they are more relevant to protein function. Synonymous SNPs may have a role in the amount of protein that is expressed in the cell by having an effect on the stability of the message. The nsSNPs are likely random mutations and it is of interest to map those of all members of this transport protein family onto a single transport protein of this family to determine whether the nsSNPs form clusters and whether these clusters are in regions of the protein that are less sensitive to mutations. The human mitochondrial phosphate transport protein (PTP) was chosen. The yeast mitochondrial phosphate transport protein with the same physiological role has been extensively characterized with single site mutations and function-relevant regions of the protein have been identified [5] . Fig. 1 shows the nsSNPs of the members of the mitochondrial transport protein family as projected onto the human mitochondrial phosphate transporter (NP_002626 in Table 1 ). These projections were obtained in the following manner. The sequence of each protein of Table 1 was compared to the protein structures in the protein data bank (PDB) by using the mGenThreader program (http://bioinf.cs.ucl.ac.uk/psipred/psiform.html). All proteins in Table 1 showed the best fit with the structure of the a SF is subfamily, i.e. members have at least one transmembrane helix sequence (H1, H3, or H5, e.g. see Fig. 1 and Ref. [1] ) with similarity E-value of less than 1e −03 . b NCBI is the National Center for Biotechnology Information with detailed information on the protein/gene under the accession number (http://www.ncbi.nlm.nih. gov/RefSeq/). SLC25 is their designation for this transporter family with A1 to A37 being the identification (ID) numbers of those members of this transporter family that are part of their official family. Iso a or iso b refer to isoforms of the transporters. c Label refers to transported substrate if it has been identified, a common name or database designation depending on what is available. ADP/ATP T3 (adenine nucleotide exchange, T3 isoform), UCP (uncoupling protein), aralar (Ca++-stimulated aspartate-glutamate transporter), citrin (Ca++-binding aspartate-glutamate carrier), BCMP (mitochondrial carrier protein in neurons), KMCP (kidney mitochondrial carrier protein), APC (ATP-Mg/Pi carrier), SCaMC (short Ca++-dependent mitochondrial carrier), AdoMet (S-adenosylmethionine), MRS (mitochondrial RNA splicing). d rs is number of amino acid residues in the protein. e cr (amino acid of contig reference sequence followed by its location counted from the N-terminal), ns (nonsynonymous substitution is when the allele has a new codon at that location that encodes a different amino acid), SNP (single nucleotide polymorphism, for such a nucleotide sequence variation to be considered a SNP it must occur in at least 1% of the population) (http://www.ncbi.nlm.nih.gov/SNP). f Location (mutation sites were projected onto human PTP (NP_002626 or SLC25 A3 iso b) by sequence alignments that include predicted and actual helices. NT and CT are protein regions beyond N-terminal of H1 and C-terminal of H6. For other abbreviations see Fig. 1 . (http://bioinf.cs.ucl.ac.uk/psipred/psiform.html)); location refers to protein regions as in Fig. 1. g Many relevant references when not cited directly are cited under the NCBI accession number or in Ref. [1] .
bovine ADP/ATP T1 transporter subunit/carboxyatractyloside complex [6] . The program also yields an alignment of the two protein sequences, e.g., human sample sequence with a mutation and bovine ADP/ATP T1 transporter sequence, taking account of predicted and actual helices. Such an alignment was used to identify the residue in the bovine ADP/ATP T1 transporter subunit similar to the nsSNP-related amino acid of the human sample sequence. Then the same protein sequence alignment between the human mitochondrial phosphate transporter and the bovine ADP/ATP T1 transporter made the assignment of the nsSNPrelated amino acid of the sample sequence in the human phosphate transporter possible. Fig. 1 shows that the nsSNP-related mutations fall into groups or clusters. Even more interesting is that they are absent from certain regions of the protein. Thus along helix 1 (H1) there are some regions without mutations. There are none near Cys26 Fig. 2 . Human disease causing replacement mutations (solid red) of the human mitochondrial transport proteins and replacement mutations that completely or severely inhibit phosphate transport activity (blue circles) of the yeast mitochondrial PTP are projected onto the topological map of the human mitochondrial PTP. Fig. 1 . Replacement mutations due to nsSNPs of the human mitochondrial transport proteins projected (see text) onto the topological diagram of the human mitochondrial phosphate transport protein (PTP) (NP_002626). The red circled residues identify locations of these replacement mutations. The number within each circle indicates the number of mutations at that location. Locations with more than one of these mutations show a red circle with a proportionally heavier circumference. The helices are indicated (H1 to H6) and so are the three short matrix-side helices (h12, h34, h56). Also the matrix loops (LM1, LM2, LM3) and the cytosolic loops (LC1, LC2) are indicated.
which has been suggested to be a contact site between the subunits of the homodimeric PTP [7] and thus of key mechanistic importance. The region near the C-terminal of this helix 1 has also been shown with site-directed mutagenesis and inhibitor binding studies to be critically important for the function of PTP. Again, there are no mutations in this region. The region around His30 is critical but unique only to the phosphate transporter (PTP). It has been suggested to be part of the mechanism that links proton transport to phosphate transport within PTP [8] . This seems to be not critical to some of the other transporters since nsSNPs are located in this region and especially at the His30 site. Short helix h12 is also of interest since it has been demonstrated to be at or near the intersubunit site of the bovine ADP/ATP transporter, i.e., this has been demonstrated by the formation of a transport-inhibiting disulfide in only the m-state or the no-inhibitor-state of the transporter [9] . Thus this region of the transporters of this family must also be critical to the transport process in general and thus most sensitive to mutations. Helices 2, 3, 4 and 5 also have patches of 12 to 15 residues without mutation. This seems to be less so for helix 6. Of interest is also that the C-terminal amino acids of the protein (C-terminal of helix 6 to C-terminal of the protein) are without mutations. However there could be reasons for that, i.e., other proteins have shorter C-terminal sequence beyond helix 6 and have no amino acids/mutations to be projected onto the Cterminal amino acids of PTP.
It should also be noted that nothing is known about the human individuals from whom these DNA samples were obtained. Thus it is not known for most of these transport proteins which mutations affect their function in a deleterious manner, i.e., what kind of substitutions are tolerated at which locations. It appears however as if there are regions that are mechanistically important to all of these transport proteins as discussed earlier. Fig. 2 shows replacement mutations that have been identified as causing human diseases (Table 1) . Also in Fig. 2 are shown the locations of replacement mutations that severely or totally inhibit phosphate transport [5] . A most obvious difference between Figs. 1 and 2 is that the collection of disease causing human mutations fall into the C-terminal regions of helices 1, 3, and 5 where substitution have the most dramatic effect on transport activities in all the transporters that have been characterized. It should also be noted that there are three mutations in short helix h12 which showed no nsSNP-related mutation in Fig. 1 . It is also quite significant that while five amino acids of helix 2 and near the N-terminal of helix 2 are located along the same surface of the helix, each blocking transport severely upon replacement ( Fig. 2 and Ref. [5] ), four amino acids that upon replacement cause human diseases are similarly located along one side of helix 6 ( Fig. 2) . Of interest is also that almost all amino acids that upon replacement yield human diseases are located within helices (Fig. 2 ). Fig. 3 shows a combination of both the nsSNP-related mutations and the disease-causing mutations. There is little overlap between their locations. However they do complement each other by often being located on the same side of a helix surface. None of the mutations that cause truncation or elongation of proteins (frame shifts or exon skipping) are listed in Table 1 . Often proteins with such mutations in their genes have a very short half life in the membrane and become often undetectable.
It will be interesting to determine whether SNP-related mutations of mitochondrial proteins in general or the transporters specifically will permit the identification of individuals with a higher susceptibility towards some diseases and with smaller or larger side effects from some pharmaceuticals.
Note added in proof
Mutation (Pro206Leu) (F. Molinari, A. Raas-Rothschild, M. Rio, G. Fiermonte, F. Encha-Razavi, L. Palmieri, F. Palmieri, Z. Ben-Neriah, N. Kadhom, M. Vekemans, T. Attie-Bitach, A. Munnich, P. Rustin, L. Colleaux, Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy, Am. J. Hum. Genet. 76 (2005) 334-339.) in human glutamate 1 (NP_078974.1, SLC25A22) is located at Ala186 in Figure 2 (solid red, H4) and Figure 3 (solid blue, H4 ).
